Tiziana Life Sciences Plc (TILS) - Financial and Strategic SWOT Analysis Review

Tiziana Life Sciences Plc (TILS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - Analyst’s summarization of the company’s business strategy.
• SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Tiziana Life Sciences Ltd (Tiziana), formerly Tiziana Life Sciences Plc, is a clinical-stage biotechnology company that discovers and develops drugs to treat inflammatory diseases and cancers. Its lead product candidate, Milciclib (TZLS-201), intended for the treatment of thymic carcinoma. The company's other clinical programs includes Foralumab (TZLS-401), a human engineered anti-human CD3 antibody intended for the treatment of Crohn’s disease and Nonalcoholic steatohepatitis. The company’s preclinical stage candidates include anti-IL6R (TZLS-501), a fully human anti-IL-6R monoclonal antibody targeting the interleukin-6 receptor. Tiziana is headquartered in Hamilton, Bermuda, the UK.

Tiziana Life Sciences Plc Key Recent Developments

Oct 19, 2022: Tiziana Life Sciences Invites You to Join Us at The ThinkEquity Conference
Sep 28, 2022: Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the Preserving the Brain Scientific Conference and Exhibit at the Fondazione Prada in Milan
Jun 08, 2022: Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab
Jan 13, 2022: Tiziana Life Sciences Announces Death of Director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company